Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for biomarkers to predict brain vessel disease

NCT ID NCT06960538

Knowledge-focused Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 200 people with cerebral amyloid angiopathy (CAA), a condition where protein builds up in brain blood vessels, raising the risk of bleeding and cognitive decline. Researchers collected clinical data, brain scans, and samples of spinal fluid and blood to find markers that could help predict how the disease will progress. The goal is to improve early diagnosis and personalize treatment, but this is an observational study, not a test of a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward better ways to diagnose and predict the progression of cerebral amyloid angiopathy, potentially leading to personalized treatment targets.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly provide a new therapy. The findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Nov 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with possible or probable CAA identified on brain MRI according to modified Boston Neuroradiological Criteria 2.0 regardless of age.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients of either sex over 18 years of age; * patients with possible and probable symptomatic or asymptomatic CAA with or without histological demonstration (modified Boston criteria); * patients who have had at least one brain MRI. Exclusion Criteria: * patients who have contraindications to undergoing brain MRI (e.g., pacemaker, incompatible mechanical valves, claustrophobia); * patients who have contraindications to or refuse to undergo lumbar puncture; * patients who are unable to provide informed consent for the study due to aphasic or cognitive impairment; * patients who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caa - cerebral amyloid angiopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral amyloid angiopathy Cerebral Amyloid Angiopathy, Familial

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Caa - cerebral amyloid angiopathy Cerebral amyloid angiopathy

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.